Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 14, 2020 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Provides Business Update and Announces Fiscal Year 2019 Financial Results

NDA (New Drug Application) and Marketing Authorization Application (MAA) completed in February 2020Commercial readiness activities in U.S. underway for potential launch of PEDMARKTM, if approved, in...
February 11, 2020 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for PEDMARK™ and Also Submits Marketing Authorization Application (MAA) to European Medicines Agency

RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq:FENC; TSX: FRX), a specialty pharmaceutical company, today announced it has completed its rolling...
November 12, 2019 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Provides Business Update and Announces Third Quarter 2019 Financial Results

NDA (New Drug Application) for PEDMARKTM to be completed in early 2020Strong financial position with $15.2 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE)...
October 02, 2019 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019

RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
September 24, 2019 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Appoints Jodi A. Cook, PhD to Its Board of Directors

RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
September 09, 2019 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Appoints Shubh Goel as Chief Commercial Officer

RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a...
August 09, 2019 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results

Anticipate PEDMARK™ New Drug Application (NDA) completion by early 2020Strong financial position with $17.5 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2019 (GLOBE NEWSWIRE)...
June 19, 2019 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 19, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy...
May 09, 2019 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Provides Business Update and Announces First Quarter 2019 Financial Results

Targeting New Drug Application to U.S. FDA for PEDMARKTM in late 2019 to early 2020Strong financial position with $20.2 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., May 09, 2019 ...
March 13, 2019 06:19 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Provides Business Update and Announces Fiscal Year 2018 Financial Results

Initiated rolling New Drug Application to U.S. FDA for PEDMARKTMSecured $12. 5 million debt financing to support a potential commercial launch Strong financial position with $22.8 million in cash and...